SEC Signals Broad Enforcement Push with New Unit, FDA Pact, and Fraud Suits
Recent SEC actions, including a new accounting fraud unit and an information-sharing deal with the FDA, signal heightened scrutiny for public companies, life sciences firms, private funds, and their executives.
The SEC has signaled a broad enforcement push through several recent actions. The agency established a new Financial Reporting and Accounting Unit within its Enforcement Division, designed to focus resources on complex accounting fraud and auditor misconduct. It also entered into a three-year memorandum of understanding with the FDA to streamline access to nonpublic information, enhancing its oversight of public life sciences companies' disclosures regarding clinical trials and product approvals.
These structural changes are accompanied by significant enforcement actions, including charges against executives in cases involving alleged asset-backed securities fraud, a major crypto Ponzi scheme, and misconduct by private fund advisers managing pre-IPO investments. These cases show the SEC's continued focus on individual accountability, transparency in private markets, and policing of conflicts like hidden fees and improper principal transactions. Counsel for public companies, asset managers, and life sciences firms should note the clear direction of the SEC's enforcement priorities and anticipate heightened scrutiny in these areas.